Introduction
============

Chronic obstructive pulmonary disease (COPD) is an important multicomponent chronic lung disorder that causes substantial disability, significantly impairs the health-related quality of life, and increases the risk of death in individuals with moderate to severe airway obstruction.[@b1-copd-7-271]--[@b8-copd-7-271] Epidemiologic evidence suggests that prevalence of COPD ranges from 4% to 20% in adults over 40 years of age, with latest estimates from the World Health Organization indicating about 210 million people being affected worldwide.[@b4-copd-7-271] However, it is likely that this number is underestimated as a consequence of differences in diagnostic criteria employed and because the disease is often not diagnosed or is misdiagnosed in the early stages.[@b4-copd-7-271],[@b5-copd-7-271] There is a considerable difference in the prevalence of COPD between low- to middle-income and high-income countries.[@b4-copd-7-271]

The Global Initiative for Chronic Obstructive Lung Disease (GOLD)[@b5-copd-7-271] suggests that although COPD is not a curable disease, it is nevertheless preventable and treatable. However, a constraint in optimal management of COPD patients is that the majority of COPD patients are usually first seen and treated by primary care physicians, who may or may not, for a variety of reasons, diagnose or treat patients appropriately.[@b9-copd-7-271],[@b10-copd-7-271] Indeed, despite the availability of international[@b5-copd-7-271],[@b7-copd-7-271],[@b11-copd-7-271] and national clinical guidelines for the management of COPD,[@b12-copd-7-271]--[@b15-copd-7-271] the disease commonly remains undiagnosed,[@b15-copd-7-271],[@b16-copd-7-271] or is diagnosed only at an advanced stage when the clinical symptoms become apparent and the disease is associated with substantial end-organ damage.[@b16-copd-7-271]--[@b18-copd-7-271] Furthermore, once COPD is diagnosed, it is often undertreated or is treated inappropriately.[@b16-copd-7-271],[@b19-copd-7-271],[@b20-copd-7-271] Misdiagnosis of COPD is also quite common,[@b20-copd-7-271]--[@b22-copd-7-271] with up to 25% of patients over 40 years old with COPD being labeled as having asthma[@b21-copd-7-271],[@b22-copd-7-271] and, conversely, about 7% of patients with asthma being labeled as having COPD.[@b20-copd-7-271] Moreover, many patients identified as COPD patients using the *COPD International Classification of Diseases, 9th Revision, Clinical Modification* diagnostic codes do not have airflow obstruction when they undergo spirometry.[@b23-copd-7-271]

Information available to date on the management of COPD patients in primary care is limited and mostly comes from Western countries with established national and/or regional management programs for COPD. In view of these findings, the authors undertook a study to survey general practitioners (GPs) in non-European Union/non-US territories across the Asia-Pacific region, Africa, eastern Europe, and Latin America in order to understand how GPs approached COPD diagnosis and treatment in these regions.

Methods
=======

A group of physicians from Argentina, Australia, Brazil, China, Hong Kong, Japan, Mexico, Russia, South Africa, South Korea, Taiwan, and Turkey who were experts in the field of chronic respiratory diseases was assembled in March 2010, through an unrestricted grant from GlaxoSmithKline. This group was provided with a broad-based brief to explore the management of COPD patients by GPs in their respective territories. Following initial group discussions, it became clear that there was a common perception that poor management, including late diagnosis and inappropriate treatment of COPD patients, was a major problem globally. Moreover, this appeared to be driven predominantly by the clinical practice of GPs; however, there were little data to confirm this observation.

To test this hypothesis, a pilot survey was conducted to evaluate the GPs' knowledge, understanding, and management of COPD, irrespective of the number of years of their experience as practicing physicians, in each of the twelve territories represented by the members of the expert group. A short and easy-to-administer questionnaire ([Appendix 1](#app1-copd-7-271){ref-type="app"}) comprising 20 questions was developed by informative discussion and general consensus among members of the expert group. Prior to finalization, the members of the expert group translated the questionnaire into the native languages of their respective territories, and these translated questionnaires were then validated by piloting among small groups of GPs and professional physicians in the respective territories. The final translated and validated questionnaires were then administered in the different territories as a web-based survey.

Synovate Healthcare, London, UK (an independent health care research consultancy firm specializing in such surveys) recruited participants from a panel of self-registered GPs from different regions across each of the twelve territories, creating and managing the panel between 2006 and 2011. All participants responded to a request to participate in the study and all were nominally compensated for their time, with a payment of between £14 and £44, depending on territory.

A total of 813 questionnaire surveys were conducted, of which the first 50 fully completed questionnaires for each territory were selected, and the remaining questionnaires excluded from the final analysis (109 incomplete questionnaires and 104 fully completed questionnaires after the quota was reached). A total of 600 responses from GPs were included in this analysis. The sample size was determined based on advice from Synovate Healthcare, who indicated that, based on experience of such studies, n = 30/territory was enough to get a "signal," and thus n = 50/territory would be appropriate for the study.

Data from all participants were collated in a dedicated database, which was also set up and managed by Synovate Healthcare.

Results
=======

[Table 1](#t1-copd-7-271){ref-type="table"} shows the demographics of the GP participants. Assessment of age distribution indicated that Mexico and Russia had the youngest GPs; for example, 92% of GPs in Mexico were under 40 years of age. In contrast, Argentina (52%) and Australia (46%) had the highest numbers of GPs over 50 years of age, with 2% of GPs from Argentina being older than 70 years. Similarly, 6% of GPs from Hong Kong were older than 70 years. The majority of GPs surveyed were male (overall mean of 73%), with Japan and South Korea having almost completely male GP practices. However, females comprised the majority of the GPs in China and Russia. Although the overall mean number of years in practice for the sample was 15.9 years, assessment by territory indicated that the mean number of years in practice was directly correlated with the age of the GPs. Thus, the GPs from Mexico were the least experienced (mean of 5.7 years) and the GPs from Argentina (mean of 23.3 years) and Australia (mean of 22.5 years) were the most experienced.

Understanding of prevalence and risk factors
--------------------------------------------

The GPs' understanding of the prevalence of and risk factors associated with COPD was assessed according to their responses to questions 7 and 8, respectively, from the survey questionnaire ([Appendix 1](#app1-copd-7-271){ref-type="app"}). While a mean of 35.5% of the GPs (range 8%--64%) surveyed reported a prevalence rate of over 15% in their country, a mean of 10.3% of the GPs (range 0%--24%) reported a prevalence rate below 5% ([Figure 1](#f1-copd-7-271){ref-type="fig"}). Moreover, relatively large numbers of GPs from Argentina (14%), China (12%), and Taiwan (16%) did not have any idea of the prevalence of COPD in their respective territories.

Assessment of the GPs' knowledge of the major risk factors associated with COPD showed that although the majority of the GPs (94%) rated smoking to be the top risk factor, 38% of GPs surveyed also rated asthma to be the next most important risk factor across all territories. Interestingly, although many clinicians regard hereditary factors as being important, only 9% of the GPs also considered this to be the case. Furthermore, 6% of GPs also considered tuberculosis to be an important risk factor for COPD.

Diagnosis
---------

The GPs' practices for diagnosis of COPD were assessed according to their responses to Question 12 from the survey questionnaire ([Appendix 1](#app1-copd-7-271){ref-type="app"}). Symptoms and spirometry were the most frequently reported routine tools used to diagnose subjects with COPD (mean of 56.5% of first or second mentions for symptoms, with a range of from 26% \[South Africa\] to 76% \[Argentina/Hong Kong\]; mean of 52.8% of first or second mentions for spirometry, with a range of from 18% \[Turkey\] to 84% \[Australia\]) ([Table 2](#t2-copd-7-271){ref-type="table"}). Interestingly, GPs from South Africa tended to underreport the use of symptoms and spirometry (26% of first and second mentions for symptoms and 20% of first and second mentions for spirometry) and overreport the use of blood tests (50% of first and second mentions) as routine diagnostic tools for COPD, compared with their peers from other territories ([Table 2](#t2-copd-7-271){ref-type="table"}). However, when considering all mentions of routine tools, instead of only first and second mentions, the reported use of the chest X-ray became prominent in all territories and actually exceeded the reports for spirometry and/or symptoms in five of the twelve territories (Hong Kong, Mexico, Russia, South Africa, South Korea) surveyed ([Table 2](#t2-copd-7-271){ref-type="table"}). Moreover, the survey demonstrated that the underutilization of spirometry in most territories was apparent despite the GPs having ready access to the technique ([Table 3](#t3-copd-7-271){ref-type="table"}).

Initiation and management of treatment
--------------------------------------

The GPs' practices for initiation and management of treatment for COPD were assessed according to their responses to questions 13 and 14, respectively, from the survey questionnaire ([Appendix 1](#app1-copd-7-271){ref-type="app"}). Although symptoms and spirometry often guided the GPs' choice of initial treatment in the survey, there was underrecognition of the importance of exacerbation history as an important factor of COPD and its initial management in most countries (median 4%; range 0%--8%) apart from China (22%). Indeed, exacerbation history was not mentioned as one of the three most important factors in any territory other than Brazil and Taiwan. Similarly, exacerbation history was not even considered to be important for the ongoing management of patients by the majority of the physicians surveyed in four of the twelve territories, including China, Hong Kong, Japan, and South Africa ([Figure 2](#f2-copd-7-271){ref-type="fig"}).

Reference to guidelines
-----------------------

The GPs' practices for use of COPD guidelines were assessed according to their responses to questions 15--17 from the survey questionnaire ([Appendix 1](#app1-copd-7-271){ref-type="app"}). Roughly two out of three GPs in the sample reported that COPD guidelines informed their management practices ([Figure 3](#f3-copd-7-271){ref-type="fig"}). Physicians reported the use of a wide variety of guidelines, of which institutional and organizational guidelines were used more frequently than the GOLD guidelines.[@b5-copd-7-271] Indeed, the GOLD guidelines[@b5-copd-7-271] were not mentioned by the sample of GPs from China, South Africa, or Turkey, and the International Primary Care and Respiratory Group COPD management guidelines[@b11-copd-7-271] were not mentioned at all.

While the GPs from Hong Kong and Turkey were less likely to be influenced by guidelines in the management of COPD, overall non-guideline-informed management of COPD was reported to be either a consequence of nonavailability of the guidelines to large numbers of the GPs surveyed in most of the territories or because the GPs considered the guidelines to be too long or not relevant ([Figure 3](#f3-copd-7-271){ref-type="fig"}).

Discussion
==========

The generally accepted global prevalence for COPD in adults aged 40 years and over ranges between 7% and 15%, according to the population-based BOLD, PLATINO, and Asia-Pacific studies.[@b24-copd-7-271]--[@b27-copd-7-271] This survey has demonstrated that the GPs involved in the survey tended to overestimate prevalence figures, despite a general consensus that COPD is underdiagnosed and undertreated. While population-based surveys are an important tool to provide real estimates of prevalence, it is interesting to note that there still appears to be a wide variation of awareness of these data at the GP level in territories such as Australia, Brazil, China, Hong Kong, Japan, South Africa, and Turkey, where population-based prevalence estimates have been conducted.[@b24-copd-7-271]--[@b27-copd-7-271]

The GOLD guidelines suggest that symptoms, spirometry, and exacerbation history are the most important features of the assessment of COPD patients,[@b5-copd-7-271] with spirometry particularly being advocated by international guidelines as a key aspect of diagnosis for COPD.[@b5-copd-7-271],[@b11-copd-7-271] The use of spirometry as a routine diagnostic tool was mentioned frequently in the survey, yet much research suggests that spirometry is underutilized by GPs. It is unclear if survey respondents provided answers based on best practice rather than on the reality of care. In Turkey, where access to spirometry is limited by the health care system to specialty care, the sample did reflect this reality in the GPs' responses. The overall finding for low utilization of spirometry as a diagnostic tool for COPD in the survey is in accordance with the findings of two recent prospective cross-sectional studies that investigated practice patterns of primary care physicians with experience of managing COPD patients.[@b16-copd-7-271],[@b28-copd-7-271] However, the authors of the present survey were surprised by the frequency of mentions of chest X-rays as diagnostic tools, with chest X-rays mentioned more than spirometry in some territories.

Although the authors know of no blood test currently available and recognized by the medical community for diagnosing COPD, the use of blood tests as a speculative answer to the question on routine diagnostic tools was included in the survey to determine the GPs' response. Interestingly, the survey demonstrated that in a large minority of the territories sampled, blood tests were indeed mentioned frequently, with 50% or more of GPs using this as a diagnostic tool for COPD. Moreover, there appeared to be a negative correlation between the frequency of mention of blood tests and the frequency of mention of guideline-informed management of the disease, suggesting a gross deficiency in the COPD management practice of these GPs.

A history of exacerbations is a predictor of risk for future exacerbations, more rapid decline in lung function, poorer quality of life, and increased mortality.[@b29-copd-7-271],[@b30-copd-7-271] In this survey, a history of exacerbations was not cited in most territories as an important consideration for the initiation of treatment and was not considered as important by the majority of survey respondents in Japan, Hong Kong, and South Africa. It is possible that in the current absence of a universally accepted definition of COPD exacerbation,[@b31-copd-7-271]--[@b33-copd-7-271] most GPs did not fully understand what characterized an exacerbation of COPD and therefore did not give much importance to its history.

Limitations
-----------

This survey is limited in several respects. The sample size was relatively small and might not be representative of the general GP population in larger countries with diverse regional and/or cultural differences (eg, China and Russia). However, as far as the authors are aware, it provides the only data that address these issues within the regions, and therefore it forms an important reference base for further research. Participants were recruited from a select panel of registered GPs, using a web-based approach. It is possible that survey respondents provided answers based on best care rather than on the reality of their practice. However, despite the lack of rigorous sampling strategy, there is consistency in several aspects of this report, across all territories surveyed, and the data form the basis for further, more directed studies in a larger sample size in each territory.

Conclusion
==========

This survey was conducted in territories where the views and beliefs of GPs are not usually assessed in global surveys, and therefore the results reflect opinions of frontline physicians in a variety of situations. The findings of this survey suggest that there appears to be a need for more ongoing education and information, specifically directed towards GPs outside of Europe and North America, and that global COPD guidelines appear to have limited reach and application in these areas. In particular, there appears to be a need to increase awareness of the importance and use of spirometry to confirm a COPD diagnosis and to increase awareness of exacerbations and their importance in managing COPD. Furthermore, there appears to be a need for both providing easier access to the guidelines and simplifying the guidelines, of which the latter should be done in consultation with GPs, in order that the guidelines are seen as being able to add value to their practice of managing COPD patients. The results of this survey clearly suggest that a larger prospective study of the beliefs and attitudes of GPs in non-Western countries is warranted to better establish the information on the practices/knowledge of GPs in those regions.
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![Perceived prevalence of chronic obstructive pulmonary disease (COPD) in each territory.^a^\
**Notes:** ^a^Results based on Question 7 from the COPD survey questionnaire: In your opinion, what is the prevalence of COPD in your country? (N = 600).\
**Abbreviation:** DK, don't know.](copd-7-271f1){#f1-copd-7-271}

![Ongoing treatment of chronic obstructive pulmonary disease (COPD) by general practitioners in different territories, based on symptoms, spirometry, and exacerbation history.^a^\
**Note:** ^a^Results based on Question 14 from the COPD survey questionnaire: in your practice, which of the following are important when deciding the ongoing treatment of a COPD patient? (N = 600).](copd-7-271f2){#f2-copd-7-271}

![Percentage of general practitioners managing chronic obstructive pulmonary disease (COPD) patients according to guidelines.](copd-7-271f3){#f3-copd-7-271}

###### 

Demographics of the study sample

  Variable                   Argentina   Australia   Brazil   China   Hong Kong   Japan   Mexico   Russia   South Africa   South Korea   Taiwan   Turkey
  -------------------------- ----------- ----------- -------- ------- ----------- ------- -------- -------- -------------- ------------- -------- --------
  GPs in age range (%)                                                                                                                            
   21--30 years              0           0           16       18      2           0       76       42       0              2             0        14
   31--40 years              30          14          40       46      38          34      16       36       36             24            24       42
   41--50 years              18          40          24       28      32          30      4        8        54             48            52       40
   51--60 years              36          38          18       8       10          36      4        14       10             22            18       0
   61--70 years              14          8           2        0       12          0       0        0        0              4             6        2
   \>70 years                2           0           0        0       6           0       0        0        0              0             0        0
  Gender (male, %)           70          74          74       40      88          96      64       44       66             94            86       84
  Years of practice (mean)   23.3        22.5        15.7     15.8    19.8        19.3    5.7      11.4     14.9           12.6          17.2     13.6
  GPs in practice (%)                                                                                                                             
   \<5 years                 2           0           10       8       2           0       60       14       0              20            0        14
   5--15 years               32          26          52       50      42          34      32       60       66             48            42       44
   16--25 years              20          40          18       28      30          42      6        18       30             24            44       38
   26--30 years              24          18          8        10      12          20      2        4        4              6             12       2
   \>30 years                22          16          12       4       14          4       0        4        0              2             2        2
  Patients seen per month                                                                                                                         
   Total (mean)              351         662         380      356     1090        346     202      292      429            1247          836      756
   With COPD (%)             12          10          20       25      8           17      18       17       15             7             6        12

**Abbreviations:** COPD, chronic obstructive pulmonary disease; GP, general practitioner.

###### 

Diagnosis of chronic obstructive pulmonary disease (COPD) by general practitioners (%) in different territories, based on symptoms, spirometry, chest X-ray, and blood test[a](#tfn3-copd-7-271){ref-type="table-fn"}

  Territory      Symptoms   Spirometry   Chest X-ray   Blood test                                                          
  -------------- ---------- ------------ ------------- ------------ ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  Argentina      62         14           16            8            22   26   40   12   8    22   46   24   0    2    28   70
  Australia      42         18           16            24           48   36   12   5    5    22   50   22   0    0    8    92
  Brazil         50         8            12            30           34   24   42   0    12   34   28   28   0    0    22   78
  China          32         18           28            22           40   16   38   6    14   14   54   18   0    4    50   46
  Hong Kong      68         8            4             20           10   40   12   38   16   24   42   18   0    0    4    96
  Japan          36         16           20            28           40   24   28   8    14   20   38   28   0    0    28   72
  Mexico         44         10           10            36           34   20   24   22   12   40   30   18   0    0    26   74
  Russia         46         4            24            26           22   34   40   4    22   22   52   4    10   14   54   22
  South Africa   22         4            2             72           12   8    18   62   16   20   12   52   32   18   10   40
  South Korea    30         20           8             42           40   26   10   24   22   32   28   18   4    2    14   80
  Taiwan         50         12           16            22           26   34   32   8    16   34   40   10   4    0    20   76
  Turkey         42         22           10            26           12   6    8    74   20   28   16   36   6    12   32   50

**Note:**

Results based on Question 12 from the COPD survey questionnaire: what do you routinely use to diagnose COPD in your practice? (N = 600).

###### 

Access to and use of spirometry as the first diagnostic tool for chronic obstructive pulmonary disease (COPD) in each territory

  Territory      GP access to spirometry (%)[a](#tfn5-copd-7-271){ref-type="table-fn"}   GP use of spirometry as first diagnostic tool for COPD (%)[b](#tfn6-copd-7-271){ref-type="table-fn"}
  -------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Argentina      80                                                                      22
  Australia      94                                                                      48
  Brazil         92                                                                      34
  China          64                                                                      40
  Hong Kong      46                                                                      10
  Japan          64                                                                      40
  Mexico         42                                                                      34
  Russia         96                                                                      22
  South Africa   78                                                                      12
  South Korea    60                                                                      40
  Taiwan         86                                                                      26
  Turkey         10                                                                      12

**Notes:**

Results based on Question 11 from the COPD survey questionnaire: in your practice, which of the following do you have easy access to? (N = 600);

results based on Question 12 from the COPD survey questionnaire: What do you routinely use to diagnose COPD in your practice? (N = 600).

**Abbreviation:** GP, general practitioner.

[^1]: ICON group (International COPD Network), listed in alphabetical order
